HAEHAEMONETICS CORP

NYSE haemonetics.com


$ 95.74 $ 0.93 (0.98 %)    

Friday, 17-May-2024 15:59:58 EDT
QQQ $ 451.63 $ -0.22 (-0.05 %)
DIA $ 399.76 $ 0.74 (0.19 %)
SPY $ 529.24 $ 0.76 (0.14 %)
TLT $ 91.40 $ -0.62 (-0.67 %)
GLD $ 223.63 $ 3.63 (1.65 %)
$ 95.73
$ 94.75
$ 0.00 x 0
$ 0.00 x 0
$ 94.14 - $ 95.76
$ 70.74 - $ 97.97
212,897
na
4.92B
$ 0.81
$ 38.91
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-08-2024 12-30-2023 10-Q
2 11-02-2023 09-30-2023 10-Q
3 08-08-2023 07-01-2023 10-Q
4 05-22-2023 04-01-2023 10-K
5 02-07-2023 12-31-2022 10-Q
6 11-08-2022 10-01-2022 10-Q
7 08-10-2022 07-02-2022 10-Q
8 05-25-2022 04-02-2022 10-K
9 02-08-2022 01-01-2022 10-Q
10 11-09-2021 10-02-2021 10-Q
11 08-11-2021 07-03-2021 10-Q
12 05-26-2021 04-03-2021 10-K
13 02-02-2021 12-26-2020 10-Q
14 11-04-2020 09-26-2020 10-Q
15 08-04-2020 06-27-2020 10-Q
16 05-20-2020 03-28-2020 10-K
17 02-04-2020 12-28-2019 10-Q
18 11-01-2019 09-28-2019 10-Q
19 08-06-2019 06-29-2019 10-Q
20 05-22-2019 03-30-2019 10-K
21 02-05-2019 12-29-2018 10-Q
22 11-06-2018 09-29-2018 10-Q
23 08-07-2018 06-30-2018 10-Q
24 05-23-2018 03-31-2018 10-K
25 02-06-2018 12-30-2017 10-Q
26 11-07-2017 09-30-2017 10-Q
27 08-07-2017 07-01-2017 10-Q
28 05-24-2017 04-01-2017 10-K
29 02-06-2017 12-31-2016 10-Q
30 11-07-2016 10-01-2016 10-Q
31 08-01-2016 07-02-2016 10-Q
32 06-01-2016 04-02-2016 10-K
33 02-02-2016 12-26-2015 10-Q
34 11-04-2015 09-26-2015 10-Q
35 07-30-2015 06-27-2015 10-Q
36 05-22-2015 03-28-2015 10-K
37 02-05-2015 12-27-2014 10-Q
38 11-04-2014 09-27-2014 10-Q
39 07-31-2014 06-28-2014 10-Q
40 05-22-2014 03-29-2014 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jmp-securities-maintains-market-outperform-on-haemonetics-raises-price-target-to-125

JMP Securities analyst David Turkaly maintains Haemonetics (NYSE:HAE) with a Market Outperform and raises the price target f...

 barrington-research-maintains-outperform-on-haemonetics-raises-price-target-to-107

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target f...

 needham-reiterates-hold-on-haemonetics

Needham analyst Mike Matson reiterates Haemonetics (NYSE:HAE) with a Hold.

 barrington-research-maintains-outperform-on-haemonetics-maintains-105-price-target

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and maintains $105 price target.

 haemonetics-received-510k-clearance-from-fda-for-teg-6s-hemostasis-analyzer-system-global-hemostasis-hn-assay-cartridge

This new cartridge extends Haemonetics' TEG 6s viscoelastic testing capabilities to serve fully heparinized patients in adu...

 barrington-research-reiterates-outperform-on-haemonetics-maintains-105-price-target

Barrington Research analyst Michael Petusky reiterates Haemonetics (NYSE:HAE) with a Outperform and maintains $105 price tar...

 haemonetics-q3-adjusted-eps-104-beats-094-estimate-sales-33625m-beat-32029m-estimate

Haemonetics (NYSE:HAE) reported quarterly earnings of $1.04 per share which beat the analyst consensus estimate of $0.94 by 10....

 earnings-scheduled-for-february-8-2024

Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share ...

 barrington-research-maintains-outperform-on-haemonetics-lowers-price-target-to-105

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and lowers the price target f...

 haemonetics-q2-2024-adj-eps-099-beats-089-estimate-sales-31818m-beat-31312m-estimate

Haemonetics (NYSE:HAE) reported quarterly earnings of $0.99 per share which beat the analyst consensus estimate of $0.89 by 11....

 earnings-scheduled-for-november-2-2023

Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION